HCG Founder Dr. B.S. Ajaikumar Launches IHF: A Healthcare-Focused Private Equity Fund

Written by Arushi Sharma

Dr. B.S. Ajaikumar launches Inviga Healthcare Fund (IHF) to empower entrepreneurs and drive change in Indian healthcare. With an initial close of US $20 million, IHF aims to revolutionize healthcare accessibility, affordability, and quality.

HCG Founder Dr. B.S. Ajaikumar Launches IHF: A Healthcare-Focused Private Equity Fund
Dr. B.S. Ajaikumar introduces Inviga Healthcare Fund, aiming to revolutionize healthcare accessibility and quality in India.

Dr. B.S. Ajaikumar, renowned Doctorpreneur and Founder of HealthCare Global Enterprises Ltd (HCG), has introduced Inviga Healthcare Fund (IHF), a thematic healthcare-focused private equity fund headquartered in Bengaluru.

Co-founded by Ajay Garg, Founder and Managing Director of Equirus Capital, IHF aims to revolutionize healthcare accessibility, affordability, and quality across all sections of society. With an initial close of US $20 million, the fund is set to empower entrepreneurs and drive meaningful change throughout the Indian healthcare value chain.

Dr. Ajaikumar expressed his vision for IHF, stating, "In my over 35 years as a doctor-entrepreneur in India, I have witnessed both the strengths and weaknesses of our healthcare system. Inviga Health Fund is my response, embodying my desire to provide high-quality healthcare to all sections of society while supporting healthcare entrepreneurs as primary business drivers. Through our investments, we aim to foster clinical excellence, drive social impact, and build sustainable businesses."

Garg highlighted the transformative potential of the fund, noting, "A doctor-driven thematic healthcare and life sciences fund in India is rare. This unique perspective helps bridge technical barriers between healthcare entrepreneurs and financiers, contributing significantly to the progress of Indian healthcare."

In its inaugural investment, Inviga Healthcare Fund has announced support for Mynvax, a biotech start-up focusing on developing recombinant vaccines for human respiratory viral diseases, including seasonal influenza and COVID-19.

Inviga will back healthcare and pharmaceutical/life science enterprises across the value chain, leveraging its sector-specific knowledge, global connections, and blend of entrepreneurial, clinical, investment, banking, and executive management expertise.

Share article